CytomX Therapeutics (CTMX) Aktienübersicht
CytomX Therapeutics, Inc. ist ein auf Onkologie spezialisiertes biopharmazeutisches Unternehmen, das sich auf die Entwicklung wirksamer Biologika zur Behandlung der Mikroumgebung von Tumoren konzentriert. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
CTMX Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
CytomX Therapeutics, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$3.82 |
| 52-Wochen-Hoch | US$8.21 |
| 52-Wochen-Tief | US$1.72 |
| Beta | 2.08 |
| 1 Monat Veränderung | 27.33% |
| 3 Monate Veränderung | -13.18% |
| 1 Jahr Veränderung | 52.80% |
| 3 Jahre Veränderung | 113.41% |
| 5 Jahre Veränderung | -37.07% |
| Veränderung seit IPO | -70.39% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 25
CTMX: De Risked Epithelial Program And Pullback Will Support Future Repricing
CytomX Therapeutics' analyst fair value estimate has shifted from $10.00 to $16.00, with analysts pointing to its de risked epithelial cell adhesion molecule antibody drug conjugate, the ability to manage toxicity risks, and the recent pullback in the stock as key reasons for the updated view. Analyst Commentary Recent research coverage on CytomX Therapeutics highlights growing interest in the company’s epithelial cell adhesion molecule antibody drug conjugate program.
Narrativ-Update • Jun 11
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Analysts have nudged their average price target for CytomX Therapeutics higher into the mid teens, citing stronger conviction in the late line colorectal cancer potential of varsetatug masetecan and CX-2051 following Phase 1 expansion data and a series of recent target increases that include moves to $11, $12 and $17. Analyst Commentary Recent research updates on CytomX Therapeutics cluster around two themes, the commercial potential of varsetatug masetecan and CX-2051 in colorectal and colon cancer, and how much risk is acceptable at current valuation levels.Narrativ-Update • May 28
CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects
Analysts have trimmed their average price target for CytomX Therapeutics by about $1.22, citing updated expectations for revenue growth, profitability and future P/E. They still point to supportive recent research that highlights the potential of Varseta-M and CX-2051 in colorectal cancer.Seeking Alpha • May 26
CytomX Therapeutics: Cashed Up With Catalysts Ahead
Summary In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand. CTMX should report updated data from its monotherapy work with Varseta-M in H2'26, and could even begin a registrational trial in H1'27. Read the full article on Seeking AlphaRecent updates
Narrativ-Update • Jun 25
CTMX: De Risked Epithelial Program And Pullback Will Support Future Repricing
CytomX Therapeutics' analyst fair value estimate has shifted from $10.00 to $16.00, with analysts pointing to its de risked epithelial cell adhesion molecule antibody drug conjugate, the ability to manage toxicity risks, and the recent pullback in the stock as key reasons for the updated view. Analyst Commentary Recent research coverage on CytomX Therapeutics highlights growing interest in the company’s epithelial cell adhesion molecule antibody drug conjugate program.Narrativ-Update • Jun 11
CTMX: Late-Line Colorectal Cancer Data Will Drive Upward Repricing Expectations
Analysts have nudged their average price target for CytomX Therapeutics higher into the mid teens, citing stronger conviction in the late line colorectal cancer potential of varsetatug masetecan and CX-2051 following Phase 1 expansion data and a series of recent target increases that include moves to $11, $12 and $17. Analyst Commentary Recent research updates on CytomX Therapeutics cluster around two themes, the commercial potential of varsetatug masetecan and CX-2051 in colorectal and colon cancer, and how much risk is acceptable at current valuation levels.Narrativ-Update • May 28
CTMX: Late Line Colorectal Cancer Data Will Drive Bullish Repricing Prospects
Analysts have trimmed their average price target for CytomX Therapeutics by about $1.22, citing updated expectations for revenue growth, profitability and future P/E. They still point to supportive recent research that highlights the potential of Varseta-M and CX-2051 in colorectal cancer.Seeking Alpha • May 26
CytomX Therapeutics: Cashed Up With Catalysts Ahead
Summary In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although toxicity concerns can't be dismissed. Following the Q1'26 CRC data update, CTMX raised $234.2M, extending its cash runway and enabling broader Varseta-M development. CTMX's cash position of $346.7M supports operations into at least H2'28, with anticipated increased R&D spending as programs expand. CTMX should report updated data from its monotherapy work with Varseta-M in H2'26, and could even begin a registrational trial in H1'27. Read the full article on Seeking AlphaAnalyseartikel • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...Analyseartikel • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...Narrativ-Update • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.Narrativ-Update • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.Narrativ-Update • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Narrativ-Update • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.Narrativ-Update • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.Narrativ-Update • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.Analyseartikel • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...Narrativ-Update • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.Narrativ-Update • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.Narrativ-Update • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.Narrativ-Update • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.Narrativ-Update • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.Analyseartikel • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...Narrativ-Update • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.Narrativ-Update • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.Analyseartikel • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analyseartikel • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...Narrativ-Update • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.Analyseartikel • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyseartikel • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Analyseartikel • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...Analyseartikel • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
Neues Narrativ • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.Analyseartikel • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...Analyseartikel • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Seeking Alpha • Jul 15
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Summary CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects. Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development. The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs. CTMX has a short cash runway and potential dilution risks in the next few years. I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist. Read the full article on Seeking AlphaAktionärsrenditen
| CTMX | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 12.4% | 4.1% | 1.6% |
| 1Y | 52.8% | 41.1% | 18.6% |
Rendite im Vergleich zur Industrie: CTMX übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 41.1 erzielte.
Rendite vs. Markt: CTMX übertraf den Markt US, der im vergangenen Jahr eine Rendite von 18.6 erzielte.
Preisvolatilität
| CTMX volatility | |
|---|---|
| CTMX Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: CTMX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CTMXDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 13% auf 7% zurückgegangen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2008 | 69 | Sean McCarthy | www.cytomx.com |
CytomX Therapeutics, Inc. ist ein auf die Onkologie fokussiertes biopharmazeutisches Unternehmen, das sich auf die Entwicklung potenter Biologika zur Behandlung der Mikroumgebung von Tumoren konzentriert. Das Unternehmen nutzt die Technologie der konditionalen Aktivierungsplattform für die Forschung und Entwicklung von Biologika in der Onkologie, die die Validierung von Zielmolekülen für Antikörper-Wirkstoff-Konjugate (ADCs), die Öffnung des therapeutischen Fensters für neuartige T-Zell-Engager (TCEs), die auf solide Tumore abzielen, und die Erhöhung des therapeutischen Indexes für Immunmodulatoren wie Zytokine umfasst, sowie die PROBODY-Plattform in der präklinischen Forschung in Bereichen außerhalb der Onkologie. Darüber hinaus entwickelt das Unternehmen CX-904, einen T-Zell-bindenden bispezifischen Antikörper, der auf den epidermalen Wachstumsfaktor-Rezeptor (EGFR) auf Tumorzellen und den CD3-Rezeptor auf T-Zellen abzielt; CX-2051, einen bedingt aktivierten ADC zur Optimierung des therapeutischen Index für EpCAM-exprimierende Epithelkarzinome, einschließlich Darmkrebs; und CX-801, ein Interferon alpha-2b PROBODY-Zytokin.
CytomX Therapeutics, Inc.'s Grundlagenzusammenfassung
| CTMX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$831.63m |
| Gewinn(TTM) | -US$62.14m |
| Umsatz(TTM) | US$35.54m |
23.4x
Kurs-Umsatz-Verhältnis-13.4x
Kurs-Gewinn-Verhältnis Ist CTMX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CTMX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$35.54m |
| Kosten der Einnahmen | US$0 |
| Bruttogewinn | US$35.54m |
| Sonstige Ausgaben | US$97.69m |
| Gewinn | -US$62.14m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.29 |
| Bruttomarge | 100.00% |
| Nettogewinnspanne | -174.84% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich CTMX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/05 19:35 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
CytomX Therapeutics, Inc. wird von 16 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |